Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity. (Q47894997)

6 February 2018

title

Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity. (English)

1 reference

6 February 2018

0 references

Ming-Kang Chang

1

1 reference

6 February 2018

Ina Kramer

2

1 reference

6 February 2018

Hansjoerg Keller

3

1 reference

6 February 2018

Jonathan H Gooi

4

1 reference

6 February 2018

Corinne Collett

5

1 reference

6 February 2018

David Jenkins

6

1 reference

6 February 2018

Seth A Ettenberg

7

1 reference

6 February 2018

Feng Cong

8

1 reference

6 February 2018

Christine Halleux

9

1 reference

6 February 2018

Michaela Kneissel

10

1 reference

6 February 2018

publication date

1 January 2014

1 reference

6 February 2018

Journal of Bone and Mineral Research

published in

1 reference

6 February 2018

volume

29

1 reference

6 February 2018

issue

1

1 reference

6 February 2018

page(s)

29-42

1 reference

6 February 2018

Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation

cites work

1 reference

Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes

21 January 2018

1 reference

Essential role of beta-catenin in postnatal bone acquisition

21 January 2018

1 reference

Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis

21 January 2018

1 reference

21 January 2018

1 reference

Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6

21 January 2018

1 reference

Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor

21 January 2018

1 reference

Lrp6 hypomorphic mutation affects bone mass through bone resorption in mice and impairs interaction with Mesd

21 January 2018

1 reference

LRP6 mutation in a family with early coronary disease and metabolic risk factors

21 January 2018

1 reference

Lrp5 and Lrp6 exert overlapping functions in osteoblasts during postnatal bone acquisition

21 January 2018

1 reference

High bone mass in mice expressing a mutant LRP5 gene

21 January 2018

1 reference

High bone density due to a mutation in LDL-receptor-related protein 5

21 January 2018

1 reference

A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait

21 January 2018

1 reference

The role of Dickkopf-1 in bone development, homeostasis, and disease

21 January 2018

1 reference

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

21 January 2018

1 reference

Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein

21 January 2018

1 reference

Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease

21 January 2018

1 reference

Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease

21 January 2018

1 reference

A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population

21 January 2018

1 reference

Identification of signal peptide domain SOST mutations in autosomal dominant craniodiaphyseal dysplasia.

21 January 2018

1 reference

Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength

21 January 2018

1 reference

Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling

21 January 2018

1 reference

The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations

21 January 2018

1 reference

Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity

21 January 2018

1 reference

LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST.

21 January 2018

1 reference

Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling

21 January 2018

1 reference

SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor

21 January 2018

1 reference

Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation

21 January 2018

1 reference

Wnt antagonists bind through a short peptide to the first β-propeller domain of LRP5/6

21 January 2018

1 reference

Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies

21 January 2018

1 reference

Characterization of the interaction of sclerostin with the low density lipoprotein receptor-related protein (LRP) family of Wnt co-receptors.

21 January 2018

1 reference

Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function

21 January 2018

1 reference

Sclerostin: therapeutic horizons based upon its actions

21 January 2018

1 reference

Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice

21 January 2018

1 reference

Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog SDZ PTS 893 or human PTH(1-34).

21 January 2018

1 reference

Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee

21 January 2018

1 reference

SOST is a target gene for PTH in bone

21 January 2018

1 reference

Structural Basis of Wnt Signaling Inhibition by Dickkopf Binding to LRP5/6

21 January 2018

1 reference

Crystal structures of the extracellular domain of LRP6 and its complex with DKK1

21 January 2018

1 reference

Genetic evidence that SOST inhibits WNT signaling in the limb

21 January 2018

1 reference

Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling

21 January 2018

1 reference

Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity

21 January 2018

1 reference

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist

21 January 2018

1 reference

Sclerostin-erbB-3 interactions: modulation of erbB-3 activity by sclerostin

21 January 2018

1 reference

The sclerostin-bone protein interactome

21 January 2018

1 reference

Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum

21 January 2018

1 reference

Lrp5 functions in bone to regulate bone mass

21 January 2018

1 reference

LRP5 and LRP6 in development and disease

21 January 2018

1 reference

WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta

21 January 2018

1 reference

Mutations in WNT1 cause different forms of bone fragility

21 January 2018

1 reference

WNT1 mutations in families affected by moderately severe and progressive recessive osteogenesis imperfecta

21 January 2018

1 reference

Regulation of osteoblastogenesis and bone mass by Wnt10b

21 January 2018

1 reference

The LRP5 high-bone-mass G171V mutation disrupts LRP5 interaction with Mesd.

21 January 2018

1 reference

Genetic association study of WNT10B polymorphisms with BMD and adiposity parameters in Danish and Belgian males

21 January 2018

1 reference

An RNA-seq protocol to identify mRNA expression changes in mouse diaphyseal bone: applications in mice with bone property altering Lrp5 mutations

21 January 2018

1 reference

Genetic analyses in a sample of individuals with high or low BMD shows association with multiple Wnt pathway genes

21 January 2018

1 reference

Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity

21 January 2018

1 reference

WNT signaling in bone homeostasis and disease: from human mutations to treatments

21 January 2018

1 reference

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

21 January 2018

1 reference

Osteoporosis-pseudoglioma syndrome: description of 9 new cases and beneficial response to bisphosphonates

21 January 2018

1 reference

Wnt isoform-specific interactions with coreceptor specify inhibition or potentiation of signaling by LRP6 antibodies

21 January 2018

1 reference

Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JBMR.2059

1 reference

6 February 2018

PubMed ID

23901037

1 reference

6 February 2018